Ariel Perez retweeted
Registration is open for the Miami Cancer Institute Immunotherapies Summit for Hematologic Malignancies 🗓️ Mar 6–7, 2026 bapth.lt/ImmunoSummit
#HemeOnc #CART #AML #Lymphoma #MultipleMyeloma
Ariel Perez retweeted
Outpatient Administration of Bispecific Antibody Therapy for Hematologic Malignancies: A Practical Guide. Co-authored by @DholariaMD.
Read the full article. brnw.ch/21wYHmR
Ariel Perez retweeted
CAR-T in PCNSL #lymsm
- 67 pts, 25% CSF+, 12% eye+
- 57% axicel, 30% tisacel
- 58% CR, 1-yr PFS 50%, 1-yr OS 66%
- 2-yr RFS better if CR/PR at CAR infusion: 56% vs 28%
- 27% G3+ ICANS!
Almost all got bridging; would love to know which agents.
academic.oup.com/neuro-oncol…
Ariel Perez retweeted
An honor and a privilege to have been part of this collaborative study across frontline DLBCL trials.
Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma. Co-authored by @AshAlizadeh, @RoschewskiMD, @DrJasonWestin, @max_diehn, @Rcl14L
Read the full article. brnw.ch/21wV02q
#lymsm
Ariel Perez retweeted
But perhaps the BIGGEST change that will affect my interpretation of trials is new neutropenia cutoffs!
v5 = Gr1 is LLN to 1500, Gr2 is 1000-1500, Gr3 is 500-1000, Gr4 is <500...
Now in v6 = Gr1 is 1000-1500, Gr2 is 500-1000, Gr3 is 100-500, Gr4 is <100!!!
Ariel Perez retweeted
I was lucky to lead this @CIBMTR analysis just published in @AjHematology 👇
onlinelibrary.wiley.com/shar…
🔑 findings:
💡 CD19 CAR T-cell therapy leads to high rates of durable responses in patients with primary mediastinal large B-cell lymphoma (PMBCL): ORR 79% CRR 68% 2-year PFS 58.6%. Outcomes may be superior compared to other LBCL subtypes.
💡We observed significantly lower relapse rates in patients exposed to immune checkpoint inhibitors prior to CAR T-cell therapy with ~50% absolute reduction in relapse incidence in ICI-exposed (2-year cumulative incidence of relapse: 21.7%) compared to ICI-naive patients (41.6%).
💡Prior ICI exposure was not associated with higher rates or severity of early toxicities such as cytokine release syndrome and neurotoxicity.
❓More data needed to better characterize how ICIs impact CAR T-cell function and TME in patients with PMBCL
🙏All collaborators and co-authors @mshadman @fredhutch @NatalieGroverMD @BradHaverkos @DrMarcosdelima @AMalone2012 @LauriePearsonMD @AnnaSureda5 @Kwudhikarn @samyamshon + others not on X.
Special thanks to @MediHumdani @MedicalCollege and Senior Author Dr. Alex Herrera @cityofhope for their guidance and for putting up with me! 😅
👉Please share with your network if you learnt something with this post 🙏
#HemOnc #MedEd #lymphomasm #CARTcelltherapy
Ariel Perez retweeted
Replying to @BLLPHD
Finally, awake after a long REMS slumber!!! @ASTCT
astctjournal.org/article/S26…
Ariel Perez retweeted
Using CARTs for first relapse in myeloma.
#mmsm
open.substack.com/pub/rafael…
Ariel Perez retweeted
Thank you to @MichaelDJain from @MoffittNews for helping us create this guide and sharing his insights on life after lymphoma. #lymsm
Ariel Perez retweeted
Join Dr Ariel Perez from @MiamiCancerInst in San Juan for a weekend that brings the biggest cancer updates from #ASCO25 straight to Puerto Rico!
Don't wait!
👉 Register for free today: totalhealthoncology.com/upco…
#ASCODirect25 #CME #MedicalEducation #Oncology @app1279
Ariel Perez retweeted
A study led by Dr. Malpica of our Rare Lymphoma Section found adult T-cell leukemia or lymphoma and extranodal NKT-cell lymphoma are more prevalent among Latin Americans (LA), calling for greater LA participation in global T cell lymphoma research. tinyurl.com/PTCL-Latin
Ariel Perez retweeted
At #HOPA25 this week to connect, inspire, & recruit amazing pharmacists to join us in sunny Miami! Let’s talk opportunities, growth, and why Baptist Health South Florida might be your next chapter
#HOPA2025 #PharmacyJobs
#oncopharm tinyurl.com/4zttre85
Ariel Perez retweeted
Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: a single-centre, single-arm, phase 2 trial
@JuanAlderuccio
@TheLancetHaem
thelancet.com/journals/lanha…
Ariel Perez retweeted
A study finds Melphalan 100 mg/m² with fludarabine reduces GI toxicity and acute/chronic #GVHD compared to 140 mg/m², while maintaining similar non-relapse mortality and overall survival after allogeneic transplantation in #AML and #mdssm. astctjournal.org/article/S26…
Ariel Perez retweeted
Real-world sequential BV➡️AVD older cHL #ASH24 @app1279:
- 40 pts, med age 72, 48% extranodal
- ORR 97% (CR 71%)
- 2-yr PFS 63%, OS 83%
- 40% dc'd tx (most d/t tox); 15% G2+ PN
- 15% loss of ADLs/IADLs
Decisions regarding this regimen vs N-AVD. #lymsm cc @HayderSaeed_MD @DrAEvens
Ariel Perez retweeted
🌟Excited to announce the 14th Annual WCS | Winter Cancer Symposium!🌟
February 28 - March 2, 2025
Rio Grande, Puerto Rico
Register Now! - wintercancersymposium.com
@Flendovasc @maryjofidlerMD @blally_md @app1279 @Sonampuri @LuisRaezMD
Ariel Perez retweeted
50% of internal medicine residents are IMGs. they are the norm.
This Post is from an account that no longer exists. Learn more
Ariel Perez retweeted
Unexpected use of CD19-CAR-T cells: Point-of-care CD19-directed CAR-T cells in AML expressing CD19. 4/6 patients achieved a CR! @nagler_EBMT @sheba_medical #CART #AML sciencedirect.com/science/ar…
Ariel Perez retweeted
Our analysis of CAR-T in #PCNSL, CIBMTR
N=24; median age 57; 88% active disease; median piror Rx4; ORR 61%; 2yr OS/PFS 50%/28%; NRM 0; CRS 67%; no G3-4. ICANS 33%; 2 with grade or higher. #lymsm #CART @CatherineLeeMD @mshadman @hemant_murthy et al.
haematologica.org/haematolog…






























